This study is looking at whether a combination of three oral medications—selinexor, venetoclax, and dexamethasone—can be effective for people with multiple myeloma that has come back or not responded to previous treatments (relapsed/refractory multiple myeloma). Specifically, it's for those whose myeloma cells have a particular genetic change called translocation 11;14 (t(11;14)). The main goal is to see how many participants have their cancer respond to this treatment. You may be able to join if you are 18 or older, have a confirmed diagnosis of multiple myeloma, and meet certain other medical criteria, such as specific blood test results. The study aims to enroll 33 participants, but its current recruitment status is unclear.

Study design

This study is testing a combination of three drugs in people with relapsed/refractory multiple myeloma. It plans to include 33 participants.

What's involved

You would take selinexor, venetoclax, and dexamethasone tablets by mouth once a day as directed by the study protocol.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how many participants respond to treatment for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.